Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Attiki: International Institute of Anticancer Research
Erscheinungsjahr
2008
Quelle
MEDLINE
Beschreibungen/Notizen
Background: Chemotherapy has limited effects in the treatment of high-grade gliomas (HGGs). Valproic acid (VPA), a histone
deacetylase (HDAC) inhibitor, may sensitize HGGs to radiochemotherapy. As the drug has been given frequently as an antiepileptic
drug, a retrospective analysis was conducted to ensure relevant information was not missed before a prospective study was
launched. Materials and Methods: An analysis of 66 pediatric patients (range, 1-19 years of age) with glioblastoma multiforme
(GBM) (n=40) or anaplastic astrocytoma (AA) (n=26) was retrospectively conducted for predictors of survival and response and
for effects of VPA on outcome or toxicity. Results: The overall survival (OS) was better for AA (p=0.0114) and complete resection
(p<0.00005) and event-free survival (EFS) was better for complete resection (p=0.0049). Nine patients received VPA (for seizure)
plus further oncological treatment. The most severe adverse effect was a pulmonary embolism (n=1); no other severe side-effects
were noted. The response to nonsurgical treatment after 8 weeks was: complete response (CR): 0, partial response (PR): 3,
stable disease (SD): 4, progressive disease (PD): 2. Some of the patients with SD responded later resulting in best response:
CR:0, PR:5, SD:2, PD:2. Conclusion: Treatment with VPA plus radiochemotherapy is well tolerated with an encouraging response
rate.